A London clinic has become the first in Europe to roll out two Alzheimer’s wonder drugs privately after they were rejected ...

One described the approval of lecanemab as “no panacea” for patients, for example, while another went as far as to suggest that, in their eyes, donanemab offered “no net benefit” at all.

Two new drugs, the first capable of slowing down the debilitating progression of Alzheimer's disease, have become embroiled in one of the biggest medical controversies in recent years. Research on ...

Mike, who is from Kent, said: "I feel more confident every day." Donanemab, made by Eli Lilly, works in the same way as lecanemab - developed by companies Eisai and Biogen - which created ...

Donanemab and Lecanemab for Early Alzheimer’s: What You Need to Know Donanemab (Kisunla) and lecanemab (Leqembi) slow early-stage Alzheimer’s progression by targeting beta-amyloid ...

Donanemab works by removing a sticky protein ... We observed a similar narrative unfold this past summer when Leqembi (lecanemab) was approved by the British regulatory authority in August ...

Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based ... Eisai and Biogen's Leqembi (lecanemab) onto the US market ...

There are over 120 drugs being tested in clinical trials, and two, lecanemab and donanemab, have made headline news as the UK’s first-ever approved drugs for treating early-stage Alzheimer’s disease, ...

Drugs, including antibiotics, antivirals, vaccinations, and anti-inflammatory medications, are linked to a lower risk of ...

Not only has medical journal The Lancet added two new risk factors for the condition (high LDL cholesterol and vision loss), but dementia-slowing drugs donanemab and lecanemab were approved for ...